Literature DB >> 20974564

SEOM clinical guidelines for the treatment of advanced colorectal cancer.

Rocío García-Carbonero1, M Auxiliadora Gómez España, Enrique Casado Sáenz, Vicente Alonso Orduña, Andrés Cervantes Ruipérez, Javier Gallego Plazas, Pilar García Alfonso, Ignacio Juez Martel, Encarnación González Flores, María Lomas Garrido, Dolores Isla Casado.   

Abstract

Colorectal cancer is the first cause of cancer diagnosis in Spain. Over half of the patients are diagnosed with or will eventually develop distant metastasis. The current manuscript aims to provide synthetic practical guidelines for the therapeutic approaches in advanced disease. Available systemic therapeutic options, and integration and sequencing of chemotherapy with surgical procedures are discussed. Extent of disease, treatment objective, tumor kras mutation status, as well as patient's functional and comorbid conditions shall be considered to properly design the most adequate therapeutic strategy.

Entities:  

Mesh:

Year:  2010        PMID: 20974564     DOI: 10.1007/s12094-010-0587-4

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  23 in total

1.  Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

Authors:  Marc Peeters; Timothy Jay Price; Andrés Cervantes; Alberto F Sobrero; Michel Ducreux; Yevhen Hotko; Thierry André; Emily Chan; Florian Lordick; Cornelis J A Punt; Andrew H Strickland; Gregory Wilson; Tudor-Eliade Ciuleanu; Laslo Roman; Eric Van Cutsem; Valentina Tzekova; Simon Collins; Kelly S Oliner; Alan Rong; Jennifer Gansert
Journal:  J Clin Oncol       Date:  2010-10-04       Impact factor: 44.544

2.  Selection of patients for resection of hepatic colorectal metastases: expert consensus statement.

Authors:  Chusilp Charnsangavej; Bryan Clary; Yuman Fong; Axel Grothey; Timothy M Pawlik; Michael A Choti
Journal:  Ann Surg Oncol       Date:  2006-09-01       Impact factor: 5.344

3.  Trends in long-term survival following liver resection for hepatic colorectal metastases.

Authors:  Michael A Choti; James V Sitzmann; Marcelo F Tiburi; Wuthi Sumetchotimetha; Ram Rangsin; Richard D Schulick; Keith D Lillemoe; Charles J Yeo; John L Cameron
Journal:  Ann Surg       Date:  2002-06       Impact factor: 12.969

4.  Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.

Authors:  Fairooz F Kabbinavar; Joseph Schulz; Michael McCleod; Taral Patel; John T Hamm; J Randolph Hecht; Robert Mass; Brent Perrou; Betty Nelson; William F Novotny
Journal:  J Clin Oncol       Date:  2005-02-28       Impact factor: 44.544

Review 5.  Towards a pan-European consensus on the treatment of patients with colorectal liver metastases.

Authors:  Eric Van Cutsem; Bernard Nordlinger; Rene Adam; Claus-Henning Köhne; Carmelo Pozzo; Graeme Poston; Marc Ychou; Philippe Rougier
Journal:  Eur J Cancer       Date:  2006-08-10       Impact factor: 9.162

6.  Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.

Authors:  Alfredo Falcone; Sergio Ricci; Isa Brunetti; Elisabetta Pfanner; Giacomo Allegrini; Cecilia Barbara; Lucio Crinò; Giovanni Benedetti; Walter Evangelista; Laura Fanchini; Enrico Cortesi; Vincenzo Picone; Stefano Vitello; Silvana Chiara; Cristina Granetto; Gianfranco Porcile; Luisa Fioretto; Cinzia Orlandini; Michele Andreuccetti; Gianluca Masi
Journal:  J Clin Oncol       Date:  2007-05-01       Impact factor: 44.544

7.  FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.

Authors:  Christophe Tournigand; Thierry André; Emmanuel Achille; Gérard Lledo; Michel Flesh; Dominique Mery-Mignard; Emmanuel Quinaux; Corinne Couteau; Marc Buyse; Gérard Ganem; Bruno Landi; Philippe Colin; Christophe Louvet; Aimery de Gramont
Journal:  J Clin Oncol       Date:  2003-12-02       Impact factor: 44.544

8.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

9.  Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial.

Authors:  Matthew T Seymour; Timothy S Maughan; Jonathan A Ledermann; Clare Topham; Roger James; Stephen J Gwyther; David B Smith; Stephen Shepherd; Anthony Maraveyas; David R Ferry; Angela M Meade; Lindsay Thompson; Gareth O Griffiths; Mahesh Kb Parmar; Richard J Stephens
Journal:  Lancet       Date:  2007-07-14       Impact factor: 79.321

10.  Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.

Authors:  Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Laurence Collette; Michel Praet; Ullrich Bethe; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321

View more
  4 in total

1.  The relevance of the Spanish Society for Medical Oncology (SEOM)'s clinical oncology guidelines.

Authors:  Dolores Isla Casado; Antonio González-Martín; Emilio Alba Conejo
Journal:  Clin Transl Oncol       Date:  2010-11       Impact factor: 3.405

Review 2.  Multidisciplinary management in rectal cancer.

Authors:  Asunción Hervás Morón; María Luisa García de Paredes; Eduardo Lobo Martínez
Journal:  Clin Transl Oncol       Date:  2010-12       Impact factor: 3.405

3.  PDGFRα/β and VEGFR2 polymorphisms in colorectal cancer: incidence and implications in clinical outcome.

Authors:  Purificacion Estevez-Garcia; Angel Castaño; Ana C Martin; Fernando Lopez-Rios; Joaquin Iglesias; Sandra Muñoz-Galván; Iker Lopez-Calderero; Sonia Molina-Pinelo; Maria D Pastor; Amancio Carnero; Luis Paz-Ares; Rocio Garcia-Carbonero
Journal:  BMC Cancer       Date:  2012-11-12       Impact factor: 4.430

4.  MiR-107 and miR-99a-3p predict chemotherapy response in patients with advanced colorectal cancer.

Authors:  Sonia Molina-Pinelo; Amancio Carnero; Fernando Rivera; Purificacion Estevez-Garcia; Juan Manuel Bozada; Maria Luisa Limon; Marta Benavent; Javier Gomez; Maria Dolores Pastor; Manuel Chaves; Rocio Suarez; Luis Paz-Ares; Fernando de la Portilla; Andres Carranza-Carranza; Isabel Sevilla; Luis Vicioso; Rocio Garcia-Carbonero
Journal:  BMC Cancer       Date:  2014-09-07       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.